Psilocybin
Psyched Wellness Is Pleased To Announce Sponsorship and Activation at The Wonderland Conference in Miami on Nov 9 – 11
Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched“), a life sciences company focused on the production and…
Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched“), a life sciences company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom, is excited to announce they will be sponsoring, attending, and activating at the Wonderland Conference in Miami FL. The conference takes place November 9th to 11th. Psyched has aligned on both direct and indirect sampling initiatives with conference organizers. They will also have a booth on the conference floor to engage with consumers while speaking to their existing and expanding product line.
“We are thrilled to be back in Miami at the Wonderland Conference. It provides us with the perfect venue to meet our existing customers and to introduce Calm to the over 1500 people expected to attend. As the only company with AME-1, a proprietary extract of the Amanita Muscaria mushroom that has obtained self-Gras status (an FDA path to market for food supplements), Calm is the obvious safe, standardized, and legal choice for consumers looking for Amanita Muscaria products in the USA.”
-Jeff Stevens, Psyched Wellness Chief Executive Officer
The company invites all conference attendees to visit their booth and introduce Calm into their lives. The Psyched Wellness community can save 20% on Wonderland tickets with the code PSYCHED20 at https://wonderlandconference.com/tickets.
-
Psychedelics6 days ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psilocybin7 days ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics7 days ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Law & Regulation6 days ago
Tryp Therapeutics merger with Exopharm approved by shareholders
-
Psychedelics6 days ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics7 days ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psychedelics7 days ago
Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research
-
Psilocybin7 days ago
Psilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness